[162] conducted a phase I/II clinical trial encompassing 17 patients with non-mCRPC (nmCRPC), evaluating the safety of tumor MUC1 glycopeptide with Tn carbohydrates (Tn-MUC1). This evidence concerns the gene MUC1 and neoplasm.